Hoffmann-la Roche Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for HOFFMANN-LA ROCHE, and what generic alternatives to HOFFMANN-LA ROCHE drugs are available?
HOFFMANN-LA ROCHE has two approved drugs.
There are five US patents protecting HOFFMANN-LA ROCHE drugs.
There are one hundred and fourteen patent family members on HOFFMANN-LA ROCHE drugs in thirty-eight countries and twenty-one supplementary protection certificates in sixteen countries.
Summary for Hoffmann-la Roche
| International Patents: | 114 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Hoffmann-la Roche: | See patent lawsuits for Hoffmann-la Roche |
Drugs and US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,126,931 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 11,433,076 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,440,922 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | 5,196,438*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hoffmann-la Roche Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 107796 | ⤷ Try a Trial |
| Portugal | 2441753 | ⤷ Try a Trial |
| Canada | 2764653 | ⤷ Try a Trial |
| Denmark | 2441753 | ⤷ Try a Trial |
| China | 102459172 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann-la Roche Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0432695 | C970013 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 2441753 | 1790024-2 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ALECTINIB OR SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/16/1169/001 20170220 |
| 2441753 | C02441753/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ALECTINIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65970 26.01.2017 |
| 2441753 | PA2017017,C2441753 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216 |
| 0432695 | 96C0044 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
